An Israeli technology developed at the Weizmann Institute can determine which drug treatment is most beneficial for an individual cancer patient and which is not.
This significantly increases the chances of successful therapy and reduces ineffective treatments and unnecessary side effects from them.
The technology was developed by Curesponse and allows samples of cancerous tumors to be taken and the effectiveness of various drugs on the patient's tumor to be examined. In this way, the creators of the technology explain, it offers oncologists a tool to personalize the treatment of cancer patients.
Call cResponseTM, allows you to simultaneously examine the oncological treatments that the patient's doctor is considering on a sample of the tumor itself and receive an answer in two or three weeks as to whether the tumor responded or not, with an efficiency of 90%.
As part of the test, a sample of the tumor is taken through a biopsy or after it is removed by surgery, and then grown under unique, patent-protected conditions in the laboratory to keep the tissue alive. The test is intended for all types of solid cancer tumors, such as breast, lung, pancreas, intestine, brain, gastric, ovarian, sarcoma, and more.
Before taking a sample of the tumor, the oncologist provides Curesponse with a list of medications and drug combinations being considered for the patient.
Immediately after the tissue is removed from the patient's body, it is sent to the Cureponse laboratory and inserted into the platform, which also combines the rapid genomic sequencing test, which evaluates 57 cancer genes that can be targeted by drugs anticancer biologics that are specifically designed to target these mutations.
within 36 hours, the rapid sequencing result is received and sent to the oncologist, who decides whether to add additional medications to the list of medications being tested, based on these genetic findings.
Studies conducted by the company have shown that if the test shows that a specific drug is effective against the tumor, There is a 90% probability that the patient who receives this drug will respond well to it.